| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 抗微生物融合化合物及其用途 | CN201280011838.X | 2012-01-09 | CN103429621B | 2017-08-01 | 艾格·穆罕默德萨加夫·阿布巴卡尔; 英焕·瓮 |
| 本发明涉及一种融合蛋白，其包含至少一种1型核糖体失活蛋白，多肽B；以及至少一种能抑制病毒进入的多肽A；和/或至少一种阳离子抗微生物肽，多肽C。 | ||||||
| 2 | 用于靶向递送(包括负载物的透皮递送)的多孔纳米颗粒支撑的脂质双层(原始细胞)及其方法 | CN201280061866.2 | 2012-10-12 | CN104023711A | 2014-09-03 | C.E.阿什莉; C.J.布林克尔; E.C.卡恩斯; M.H.菲克拉扎德; L.A.费尔顿; O.内格里特; D.P.帕迪利亚; B.S.威尔金森; D.C.威尔金森; C.L.威尔曼 |
| 本发明涉及特异性靶向肝细胞和其它癌细胞的原始细胞，其包含：1)具有受支撑的脂质双层的纳米多孔二氧化硅核、至少一种促进癌细胞死亡的药剂(例如传统小分子、大分子负载物(例如，siRNA或蛋白质毒素，如蓖麻毒素A链或白喉毒素A链)，和/或在纳米多孔二氧化硅核中处理的(优选超螺旋的以更有效地将DNA封装入原始细胞)的组蛋白封装的质粒DNA，所述纳米多孔二氧化硅核任选地经核定位序列修饰以有助于在癌细胞的细胞核内定位原始细胞和表达以下肽的能力：涉及癌细胞治疗(细胞凋亡/细胞死亡)的肽，或作为报告子，一种靶向待治疗组织中的癌细胞从而使得原始细胞和靶细胞的结合是特异性的和增强的靶向肽和一种促进原始细胞和包封的负载物(包括DNA)的内体逃逸的融合肽)。本发明的原始细胞可用于治疗癌症，尤其包括使用选择性结合肝细胞组织的新型结合肽(c-MET肽)治疗肝细胞(肝)癌，或者用于癌症诊断，包括癌症治疗和药物发现。 | ||||||
| 3 | 用于治疗癌症的组合物和方法 | CN201380042750.9 | 2013-06-13 | CN105263519A | 2016-01-20 | 约翰·C·赫尔; 欧塞比奥·S·皮雷; 奥斯丁·赫尔 |
| 本发明提供了使用免疫毒素技术用于靶向SAS1B阳性癌细胞的组合物，并且公开了肾脏癌细胞和胰腺癌细胞为SAS1B阳性，而正常的肾脏细胞和胰腺细胞不是SAS1B阳性。本发明公开了尽管SAS1B只在雌性动物生长的卵母细胞的正常组织中表达，其却在男性和女性的癌症中表达。 | ||||||
| 4 | 抗微生物融合化合物及其用途 | CN201280011838.X | 2012-01-09 | CN103429621A | 2013-12-04 | 艾格·穆罕默德萨加夫·阿布巴卡尔; 英焕·瓮 |
| 本发明涉及一种融合蛋白，其包含至少一种1型核糖体失活蛋白，多肽B；以及至少一种能抑制病毒进入的多肽A；和/或至少一种阳离子抗微生物肽，多肽C。 | ||||||
| 5 | 使用α-二羰基化合物制备类毒素的方法 | CN201180041953.7 | 2011-07-18 | CN103079590A | 2013-05-01 | L·J·考尔克; G·J·菲利普; G·D·格里菲斯; D·怀特菲尔德 |
| 本发明涉及使用如乙二醛、丁二酮和苯甲酰甲醛等α-二羰基类毒素化试剂制备的类毒素的应用。所述类毒素可以用低浓度的类毒素化试剂在短的时间内、通常在少至24小时中制得，使得所述类毒素化试剂在与传统甲醛类毒素化相比时特别有利。本发明描述了使用如苯甲酰甲醛等二羰基试剂制得的类毒素，并要求保护包含所述类毒素的药物和疫苗组合物，使用此类组合物的治疗方法和通过用所述类毒素免疫接种产生的抗体以及使用如此制备的抗体的治疗方法或此类抗体的片段。 | ||||||
| 6 | NOVEL MODULATORS AND METHODS OF USE | US15956213 | 2018-04-18 | US20180237512A1 | 2018-08-23 | JOHANNES HAMPL; SCOTT J. DYLLA; ORIT FOORD; ROBERT A. STULL |
| Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided. | ||||||
| 7 | ANTIBODY-DRUG CONJUGATES AND IMMUNOTOXINS | US15116419 | 2015-02-04 | US20170007714A1 | 2017-01-12 | Roland Kontermann; Klaus Pfizenmaier; Cristina Ferrer; Myriam Fabre; Laureano Simon |
| The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed. | ||||||
| 8 | ANTIMICROBIAL FUSION COMPOUNDS AND USES THEREOF | US14845013 | 2015-09-03 | US20160068829A1 | 2016-03-10 | Muhammad Sagaf ABU BAKAR, Ag.; Eng Huan UNG |
| A fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A capable of viral entry inhibition; and/or at least one Cationic AntiMicrobial Peptide, polypeptide C. | ||||||
| 9 | Targeting ABCB5 for cancer therapy | US14251932 | 2014-04-14 | US09266946B2 | 2016-02-23 | Markus H. Frank; Natasha Y. Frank; Mohamed H. Sayegh |
| The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof. | ||||||
| 10 | POROUS NANOPARTICLE-SUPPORTED LIPID BILAYERS (PROTOCELLS) FOR TARGETED DELIVERY INCLUDING TRANSDERMAL DELIVERY OF CARGO AND METHODS THEREOF | US14350674 | 2012-10-12 | US20150272885A1 | 2015-10-01 | Carlee Erin Ashley; C. Jeffrey Brinker; Eric C. Carnes; Mohammad Houman Fekrazad; Linda A. Felton; Oscar Negrete; David Patrick Padilla; Brian S. Wilkinson; Dan C. Wilkinson; Cheryl L. Willman |
| The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery. | ||||||
| 11 | COMPOSITIONS AND METHODS FOR TREATING CANCER | US14407399 | 2013-06-13 | US20150125445A1 | 2015-05-07 | John C. Herr; Eusebio S. Pires; Austin Herr |
| The present invention provides compositions for targeting SAS1B positive cancer cells using immunotoxin technology and discloses that kidney and pancreatic cancer cells are SAS1B positive, but not normal kidney and pancreatic cells. The invention discloses that despite being expressed only in growing oocytes in females among normal tissues SAS1B is expressed in cancers of both men and women. | ||||||
| 12 | NOVEL ANTIGEN BINDING PROTEIN AND ITS USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER | US14355986 | 2012-11-05 | US20150037340A1 | 2015-02-05 | Charlotte Beau-Larvor; Liliane Goetsch; Nicolas Boute |
| The present invention relates to an antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to an antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers. | ||||||
| 13 | NOVEL MODULATORS AND METHODS OF USE | US13995086 | 2011-12-07 | US20140302034A1 | 2014-10-09 | Alex Bankovich; Orit Foord; Johannes Hampl; Scott J. Dylla |
| Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided. | ||||||
| 14 | NOVEL ANTIGEN BINDING PROTEIN AND ITS USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER | US13935918 | 2013-07-05 | US20140141023A1 | 2014-05-22 | Charlotte BEAU-LARVOR; Liliane Goetsch; Nicolas Boute |
| The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers. | ||||||
| 15 | NOVEL MODULATORS AND METHODS OF USE | US13992599 | 2011-12-07 | US20140093495A1 | 2014-04-03 | Johannes Hampl; Scott J. Dylla; Orit Foord; Robert A. Stull |
| Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided. | ||||||
| 16 | PLANT LECTINS AS CARRIERS OF ASSOCIATED DRUG SUBSTANCES INTO ANIMAL AND HUMAN CELLS | US13906203 | 2013-05-30 | US20130323221A1 | 2013-12-05 | DAVID N. RADIN |
| The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant “AB toxins” (PTB lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation. One embodiment of this invention concerns the ability of ricin toxin B subunit, as a model PTB lectin, to deliver enzyme replacement therapeutic drugs to cells of several organs of the body including the brain and central nervous system, eyes, ears, lungs, bone, heart, kidney, liver, and spleen for treating lysosomal diseases. | ||||||
| 17 | CELL-TARGETING MOLECULES COMPRISING AMINO-TERMINUS PROXIMAL OR AMINO-TERMINAL, SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS | US16013600 | 2018-06-20 | US20180291359A1 | 2018-10-11 | Eric Poma; Erin Willert; Jack Higgins; Jason Kim |
| The present invention provides cell-targeting molecules comprising binding regions for cell-type specific targeting and Shiga toxin A Subunit effector regions for Shiga toxin effector functions, wherein the Shiga toxin effector regions are at and/or proximal to an amino-terminus of a polypeptide component of the cell targeted molecule, and optionally comprising a disrupted, furin-cleavage motif between the Shiga toxin effector region and the binding region. The cell-targeting molecules of the invention exhibit a more optimized cytotoxicity and/or improved, in vivo tolerability as compared to related molecules comprising less amino-terminus proximal, Shiga toxin effector regions and/or furin-cleavage sensitive, wild-type, Shiga toxin effector regions. The cell targeting molecules of the invention have uses, such as, e.g., in methods involving targeted killing of cells, delivering exogenous materials into cells, labeling subcellular compartments of cells, and diagnosing and/or treating a variety of conditions, including cancers, tumors, other growth abnormalities, immune disorders, and microbial infections. | ||||||
| 18 | Antibody-drug conjugates and immunotoxins | US15116419 | 2015-02-04 | US10004812B2 | 2018-06-26 | Roland Kontermann; Klaus Pfizenmaier; Cristina Ferrer; Myriam Fabre; Laureano Simon |
| The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed. | ||||||
| 19 | Modulators and methods of use | US15072811 | 2016-03-17 | US09969798B2 | 2018-05-15 | Johannes Hampl; Scott J. Dylla; Orit Foord; Robert A. Stull |
| Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided. | ||||||
| 20 | Plant lectins as carriers of associated drug substances into animal and human cells | US14956001 | 2015-12-01 | US09862939B2 | 2018-01-09 | David N. Radin; Carole L. Cramer |
| The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant “AB toxins” (PTB lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation. One embodiment of this invention concerns the ability of ricin toxin B subunit, as a model PTB lectin, to deliver enzyme replacement therapeutic drugs to cells of several organs of the body including the brain and central nervous system, eyes, ears, lungs, bone, heart, kidney, liver, and spleen for treating lysosomal diseases. | ||||||
QQ群二维码
意见反馈
意见反馈